Nucleome Therapeutics nominates first preclinical development candidate
First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseases
Evolution of Nucleome’s non-coding genetics platform reveals further groundbreaking insights into disease areas of high unmet need
Oxford, UK, 07 January 2026 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a company tackling the molecular causes of inflammatory diseases through a breakthrough approach to 3D human genetics, provides an R&D update following the nomination of a preclinical development candidate for its lead first-in-class programme, NTP464. The programme will progress towards IND enabling studies from its discovery platform.
